Taysha Gene Therapies (NASDAQ:TSHA) Price Target Cut to $14.00

Taysha Gene Therapies (NASDAQ:TSHAGet Rating) had its price target lowered by investment analysts at Wells Fargo & Company from $20.00 to $14.00 in a research report issued on Monday, The Fly reports.

Several other analysts have also recently weighed in on TSHA. BTIG Research dropped their price objective on shares of Taysha Gene Therapies from $25.00 to $15.00 in a research note on Thursday, November 10th. Needham & Company LLC reduced their price target on Taysha Gene Therapies from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Tuesday, November 8th. Guggenheim lowered their price objective on Taysha Gene Therapies from $22.00 to $19.00 in a research note on Tuesday, November 8th. JMP Securities cut their target price on Taysha Gene Therapies from $22.00 to $20.00 and set a “market outperform” rating for the company in a research report on Thursday, November 10th. Finally, Canaccord Genuity Group assumed coverage on Taysha Gene Therapies in a research report on Tuesday, November 8th. They issued a “buy” rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat, Taysha Gene Therapies currently has an average rating of “Moderate Buy” and a consensus target price of $16.46.

Taysha Gene Therapies Stock Down 5.2 %

TSHA stock opened at $2.20 on Monday. The business’s fifty day moving average price is $2.15 and its two-hundred day moving average price is $3.12. The stock has a market capitalization of $90.40 million, a price-to-earnings ratio of -0.54 and a beta of 1.27. Taysha Gene Therapies has a fifty-two week low of $1.35 and a fifty-two week high of $15.34. The company has a debt-to-equity ratio of 3.40, a current ratio of 1.30 and a quick ratio of 1.30.

Insider Activity at Taysha Gene Therapies

In related news, CFO Kamran Alam sold 9,717 shares of the stock in a transaction that occurred on Monday, August 22nd. The shares were sold at an average price of $3.50, for a total value of $34,009.50. Following the completion of the transaction, the chief financial officer now owns 269,446 shares of the company’s stock, valued at approximately $943,061. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Taysha Gene Therapies news, CFO Kamran Alam sold 9,717 shares of the company’s stock in a transaction dated Monday, August 22nd. The stock was sold at an average price of $3.50, for a total value of $34,009.50. Following the completion of the transaction, the chief financial officer now owns 269,446 shares of the company’s stock, valued at approximately $943,061. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Paul B. Manning purchased 1,500,000 shares of the business’s stock in a transaction dated Monday, October 31st. The shares were purchased at an average cost of $2.00 per share, for a total transaction of $3,000,000.00. Following the completion of the purchase, the director now directly owns 1,642,202 shares of the company’s stock, valued at approximately $3,284,404. The disclosure for this purchase can be found here. 42.40% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

A number of institutional investors have recently added to or reduced their stakes in TSHA. Swiss National Bank increased its position in Taysha Gene Therapies by 9.3% during the 1st quarter. Swiss National Bank now owns 41,000 shares of the company’s stock valued at $267,000 after purchasing an additional 3,500 shares during the period. Occudo Quantitative Strategies LP increased its holdings in Taysha Gene Therapies by 17.9% in the second quarter. Occudo Quantitative Strategies LP now owns 31,030 shares of the company’s stock worth $115,000 after purchasing an additional 4,702 shares in the last quarter. Quantum Private Wealth LLC lifted its stake in Taysha Gene Therapies by 3.8% in the second quarter. Quantum Private Wealth LLC now owns 157,774 shares of the company’s stock valued at $586,000 after buying an additional 5,800 shares during the period. TimesSquare Capital Management LLC boosted its holdings in shares of Taysha Gene Therapies by 1.0% during the 1st quarter. TimesSquare Capital Management LLC now owns 665,900 shares of the company’s stock worth $4,342,000 after buying an additional 6,800 shares in the last quarter. Finally, Sargent Investment Group LLC grew its position in shares of Taysha Gene Therapies by 66.9% during the 2nd quarter. Sargent Investment Group LLC now owns 17,788 shares of the company’s stock worth $66,000 after buying an additional 7,132 shares during the period. 34.28% of the stock is owned by institutional investors.

About Taysha Gene Therapies

(Get Rating)

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis.

Further Reading

The Fly logo

Analyst Recommendations for Taysha Gene Therapies (NASDAQ:TSHA)

Receive News & Ratings for Taysha Gene Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taysha Gene Therapies and related companies with MarketBeat.com's FREE daily email newsletter.